Author

J. S. Blackburn

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Organism:zebrafish· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:imaging· 1

Frequent Co-Authors

C. N. Smith· 2 shared A. H. Cox· 1 shared B. G. Patty· 1 shared D. Deredge· 1 shared D. Lee· 1 shared D. R. Rivas· 1 shared E. C. Arvin· 1 shared E. S. Hausman· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

C. N. Smith

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Zebrafish Drug Screening Identifies Erlotinib as an Inhibitor of Wnt/β-Catenin Signaling and Self-Renewal in T-cell Acute Lymphoblastic Leukemia

M. A. Al-Hamaly, A. H. Cox, M. G. Haney, W. Zhang, E. C. Arvin, S. Sampathi, M. Wimsett, J. S. Blackburn

This study identifies Erlotinib as a Wnt/β-catenin inhibitor effective in zebrafish and human cells, reducing leukemia-initiating cell self-renewal and disease progression.

bioRxiv · Aug 28, 2023Cancer Biology

Development and validation of nanobodies specifically targeting the oncogenic Phosphatase of Regenerating Liver-3 (PRL-3)

C. N. Smith, K. Kihn, Z. A. Williamson, Y. Chernyavskyay, K. M. Chow, L. B. Hersh, K. V. Korotkov, D. Deredge, J. S. Blackburn

This paper develops and validates nanobodies that specifically target PRL-3, showing high specificity over PRL-1 and PRL-2 and providing tools to study PRL-3 function in cancer.

bioRxiv · Oct 2, 2020 · PreprintBiochemistry

A screen of FDA-approved drugs identifies inhibitors of Protein Tyrosine Phosphatase 4A3 (PTP4A3 or PRL-3)

D. R. Rivas, M. V. C. Dela Cerna, C. N. Smith, B. G. Patty, D. Lee, J. S. Blackburn

The paper screens FDA-approved drugs to identify inhibitors of PTP4A3 (PRL-3), finding five specific inhibitors and two broad inhibitors that block PRL-3-induced migration without affecting cell viability.

bioRxiv · May 24, 2020Cancer Biology

In vivo imaging defines vascular interplay in the development of lymphocytic leukemia in zebrafish models

S. Revskoy, M. E. Blair, S. M. Powell, E. S. Hausman, J. S. Blackburn

The paper uses in vivo imaging in zebrafish to study how vascular networks support leukemia cell dissemination and finds that leukemic cells use VEGFR2-microvessels during early progression.

bioRxiv · Oct 16, 2019 · PreprintCancer Biology